logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Vertex Pharmaceuticals, Inc.


USPTO Granted Patents = 1,155



Trademarks = 47

Forward Citations = 25,950

Loading Chart...
Loading Chart...

948 inventors (with patents filed for the assignee):

goldMedal Jean-Damien Charrier (139 out of 140 patents)

silverMedal Mark Thomas Miller (105 out of 111 patents)

bronzeMedal Jinglan Zhou (101 out of 104 patents)

4.  Sara Sabina Hadida Ruah (99 out of 99 patents)

5.  Ronald Marcellus Knegtel (99 out of 100 patents)

6.  Andreas Peter Termin (86 out of 98 patents)

7.  David J Lauffer (82 out of 89 patents)

8.  Guy W Bemis (82 out of 83 patents)

9.  Jason McCartney (74 out of 74 patents)

10.  Brian Richard Bear (73 out of 75 patents)

11.  Peter D J Grootenhuis (69 out of 70 patents)

12.  Steven John Durrant (69 out of 70 patents)

13.  Albert Charles Pierce (66 out of 66 patents)

14.  Paul S Charifson (63 out of 65 patents)

15.  Pan Li (58 out of 58 patents)


Core Competencies:
Cystic Fibrosis
Sodium Channel Modulators
Pancreatic Endocrine Cells
Genome Editing
APOL1 Inhibitors
Pharmaceutical Compositions
Stem Cell Differentiation
Hemoglobinopathies
DNA-PK Inhibitors
Therapeutic Delivery Devices
Alpha-1 Antitrypsin Modulators
Indole Derivatives

1,155 patents:

1. 12515028 - Multicompartment macroencapsulation devices (2026-01-06),
2. 12508231 - Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (2025-12-30),
3. 12503439 - Heteroaryl compounds for the treatment of pain (2025-12-23),
4. 12502376 - Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) (2025-12-23),
5. 12497614 - COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES (2025-12-16),
6. 12492388 - MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES (2025-12-09),
7. 12458635 - Pharmaceutical composition and administrations thereof (2025-11-04),
8. 12442020 - Materials and methods for treatment of pain related disorders (2025-10-14),
9. 12441703 - Carboxamides as modulators of sodium channels (2025-10-14),
10. 12440481 - Esters and carbamates as modulators of sodium channels (2025-10-14),
11. 12421251 - Cystic fibrosis transmembrane conductance regulator modulating agents (2025-09-23),
12. 12421249 - Inhibitors of APOL1 and methods of using same (2025-09-23),
13. 12415798 - Processes for making modulators of cystic fibrosis transmembrane conductance regulator (2025-09-16),
14. 12385013 - Differentiation of pancreatic endocrine cells (2025-08-12),
15. 12384790 - Pteridinone compounds and uses thereof (2025-08-12),
Vertex Pharmaceuticals is a global biotechnology company that aims to discover, develop, and commercialize innovative medicines for serious diseases. With a focus on cystic fibrosis and other severe pulmonary diseases, Vertex is committed to transforming patients' lives with groundbreaking therapies. Through cutting-edge scientific research and collaborations, Vertex strives to provide hope and improved treatment options to those in need.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

...
1,155 Patents

#4 in Cambridge, MA

#24 in Massachusetts

#433 in US

#869 in the World

...
Cambridge, MA, United States of America

Vertex Pharmaceuticals, Inc.

Forward Citations = 25,950

948 inventors:

goldMedal Jean-Damien Charrier (139 out of 140 patents)

silverMedal Mark Thomas Miller (105 out of 111 patents)

bronzeMedal Jinglan Zhou (101 out of 104 patents)

4.  Sara Sabina Hadida Ruah (99 out of 99 patents)

5.  Ronald Marcellus Knegtel (99 out of 100 patents)

Please report any incorrect information to support@idiyas.com
Loading…